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ABSTRACT
Objective: To estimate the costs of undiagnosed chronic
obstructive pulmonary disease (COPD) by describing inpa-
tient, outpatient, and pharmacy utilization in the years before
and after the diagnosis.
Methods: A total of 6864 patients who were enrolled in the
Lovelace Health Plan for at least 12 months during the study
period (January 1, 1999 through December 31, 2004) were
identiﬁed. The ﬁrst date that utilization was attributed to
COPD was considered the ﬁrst date of diagnosis. Each COPD
case was matched to up to three age- and sex-matched con-
trols. All utilization and direct medical costs during the study
period were compiled monthly and compared based on the
time before and after the initial diagnosis.
Results: Total costs were higher by an average of $1182 per
patient in the 2 years before the initial COPD diagnosis, and
$2489 in the 12 months just before the initial diagnosis,
compared to matched controls. Most of the higher cost for
undiagnosed COPD was attributable to hospitalizations.
Inpatient costs did not increase after the diagnosis was made,
but approximately one-third of admissions after the diagno-
sis were attributed to respiratory disease. Outpatient and
pharmacy costs did not differ substantially between cases and
matched controls until just a few months before the initial
diagnosis, but remained 50% to 100% higher than for con-
trols in the 2 years after diagnosis.
Conclusions: Undiagnosed COPD has a substantial impact
on health-care costs and utilization in this integrated
managed care system, particularly for hospitalizations.
Keywords: burden of illness, COPD, epidemiology, health-
care costs, health-care utilization.
Introduction
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death in the United States, and
its prevalence is growing, especially among women [1].
It is also a leading cause of chronic disability world-
wide [2]. Nevertheless, even with COPD’s high preva-
lence and devastating impact, undiagnosed COPD is
still a very common problem. Estimates based on
billing information and telephone surveys have sug-
gested that for every COPD patient who has been
diagnosed, there may be two or more undiagnosed
cases [1]. Surveys such as the Third National Health
and Nutrition Study (NHANES III) that have con-
ducted lung function testing among representative
samples from the general population have shown that
the majority of patients with airﬂow obstruction
proven by spirometry have not been diagnosed with
lung disease, even though undiagnosed COPD is
proven to have a negative impact on functional status
and quality of life [3,4].
Health systems have been slow to respond to the
growing COPD epidemic. One reason may be that
there are few studies describing what impact undiag-
nosed COPD has on health-care costs and utilization.
One might assume that undiagnosed COPD is not
costing the health-care system anything because there
has been no utilization attributed to it. Nevertheless,
we and others have shown that among COPD patients
utilization and costs for nonrespiratory ailments are at
least as great as those directly attributable to respira-
tory illness [5]. In fact, we have developed algorithms
that use particular aspects of this increased utilization
to identify patients at risk for undiagnosed COPD [6].
Decision-makers at managed care organizations and
other health-care leaders need information on undiag-
nosed COPD’s true impact so that they might better
understand the importance of early identiﬁcation and
management.
The overall goal of this study is to describe the costs
of undiagnosed COPD among patients enrolled in a
managed care system. To do this, we examined the
natural history of health-care utilization and costs for
COPD patients starting from the very ﬁrst day that a
patient is given the diagnosis. The costs of undiag-
nosed COPD are then examined by comparing the
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health-care utilization that COPD patients incurred in
the years before formally being diagnosed to that of
persons with similar demographic and utilization char-
acteristics who have never been diagnosed with
COPD.
Methods
Study Site, Data Abstraction, and Chart Review
All patients for this study were enrolled in the Lovelace
Health Plan (LHP), which is a staff and network
model managed care provider based in Albuquerque,
New Mexico. The LHP had approximately 240,000
members in 2001, which includes participants in their
Medicare, Medicaid, and commercial HMO pro-
grams. The LHP is the insurance component of the
Lovelace Health System, which includes four hospital
facilities and 20 outpatient centers in Northern New
Mexico. This project was reviewed and approved by
the Lovelace’s Ofﬁce of Research Administration and
Human Research Review Committee.
The data for this study were derived primarily from
the claims data routinely collected by the LHP. All
services performed for LHP members are electronically
coded with the date of service, speciﬁc type of service
according to CPT or internal service codes, and all
associated diagnoses using ICD-9 codes. The adminis-
trative data also include demographic information
such as age and sex, but abstraction of these ﬁles was
limited to only the minimum required to characterize
the patient population to comply with privacy
regulations.
The LHP administrative records do not capture
pulmonary function test data or information about
smoking or other exposures. In order to characterize
the study population in terms of the severity of airﬂow
obstruction and tobacco use, we conducted a limited
medical record review of 200 COPD patients ran-
domly selected from this cohort. Our senior abstractor,
who is also a registered nurse and has participated in
previous COPD projects, assisted with the develop-
ment of an abstraction instrument and associated pro-
tocol, abstracted all of the records, and provided a
brief synopsis of each case.
COPD Patients and Matched Controls
The COPD patients were identiﬁed using case identi-
ﬁcation methods validated in our previous studies
[7,8]. We required that patients have one inpatient or
two outpatient visits on two separate days that were
associated with a primary or secondary diagnosis of
COPD (ICD-9 codes 491.xx [emphysema], 492.x
[chronic bronchitis], or 496 [COPD-unspeciﬁed]), at
any time during the study period (January 1, 1999
through December 31, 2004). In a project that
included a comprehensive chart review of more than
2000 COPD patients, we found that more than 95%
of the patients identiﬁed by this system had two or
more types of documented clinical evidence (spirom-
etry, chest x-rays, smoking history, or chronic respira-
tory symptoms) supporting the diagnosis of COPD [8].
The ﬁrst date that one of these codes appeared in each
patient’s claims data was considered to be the very ﬁrst
date of diagnosis, which was validated in 196 of the
200 cases that were randomly selected for our chart
review.
Identical exclusion criteria were applied to COPD
patients and controls (Fig. 1). Patients who had only
one COPD code, or who had a lung disease that is not
typically included within the context of COPD, were
excluded from being either a case or a control. Only
adults who were between the ages of 40 and 90 years
at the beginning of the study period were eligible for
this study, and they had to have at least 12 months of
continuous enrollment (6 months before the very ﬁrst
COPD diagnosis, and 6 months after) in the LHP.
These criteria exclude any person who died with less
than 6 months of follow-up after their initial diagnosis
of COPD.
Each COPD patient was matched to up to three
controls by sex and age (2 years) at the time of
the initial COPD diagnosis. Control subjects were
required to have at least the minimal amount of utili-
zation required to be a COPD case (at least one hos-
pitalization or two outpatient visits during the study
period), and controls who were matched to COPD
patients who had a hospitalization during the study
period were also required to have a hospitalization.
Controls also needed to have at least 6 months of
enrollment on either side of their COPD patient’s
index date. Complete 3:1 matches were found for
98.3% of our COPD cohort.
Utilization, Cost, and Comorbidity Capture
All health-care utilization and cost data for each
COPD case and control patient during the study
period were captured. Lovelace Health System gener-
ates charges for all services administered to LHP
members, and charges are also submitted for services
administered by other network providers. To convert
charges to cost, we applied the Medicare cost-to-
charge ratios for 2003 [9]. The costs and utilization
were stratiﬁed into inpatient, outpatient, and outpa-
tient pharmacy categories, with emergency department
visits not associated with an admission included in the
outpatient category. Charges were compiled by calen-
dar month, with the month including the patient’s date
of initial diagnosis described as the index month.
To identify prognostically signiﬁcant comorbidities,
we used a modiﬁed version of the Charlson-Deyo
index that was based on outpatient utilization in the
year before the initial COPD diagnosis [10]. COPD
was not included in the calculation of this index.
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Statistical Analysis
All data were analyzed using SAS for Windows version
8.3 (SAS Institute Inc., Cary, NC, USA). Proportional
differences between groups were compared using the
Mantel-Haenszel test. Differences in utilization and
cost were tested using the Mann–Whitney rank-sum
test.
Results
The mean age of the COPD cohort at the time of initial
diagnosis (67.6  4.8 years) was not signiﬁcantly dif-
ferent from that of controls (66.2  3.6 years), and
57.1% of the cohort were female. The mean Charlson
Index in the COPD cohort was 0.67 versus 0.45 for the
controls (P < 0.001), indicating that the COPD group
had signiﬁcantlymore prognostically important comor-
bidities other than lung disease. Most of this difference
was attributable to cardiovascular complications
(arrhythmias, coronary artery disease, or congestive
heart failure), which affected 38.9% of the COPD
cohort versus 22.1% of the controls. The chart review
of 200 randomly selected COPD patients found that
56.5% (n = 113) had pulmonary function testing at
least one time in the 2 years after diagnosis, with amean
percentage of predicted FEV1 of 57.3%.Approximately
85% of those selected for the review had a documented
history of tobacco use, with a mean cigarette exposure
of 41.3 pack-years, and 45% were noted to be still
using cigarettes in the year before diagnosis.
Total direct health-care costs were higher among
COPD patients in the 24 months proceeding the index
sex
6
before
Figure 1 Flow diagram illustrating application
of chronic obstructive pulmonary disease
(COPD) case and control inclusion and exclu-
sion criteria. IP, inpatient; OP, outpatient.
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month (Fig. 2 and Table 1). The highest costs during
the study period were seen in the month of the index
date, which is largely attributable to the fact that most
COPD patients were diagnosed during an acute respi-
ratory event. In fact, COPD was ﬁrst diagnosed during
a hospitalization in 17.8% of the cohort. After the
initial COPD diagnosis, total health-care costs among
COPD patients continued at a higher monthly rate
than that seen before the diagnosis (Fig. 2). COPD
patients’ mean annual health-care costs were 24% to
36% greater than those of control patients in the
2 years before diagnosis, and 69% to 73% greater in
the 2 years after diagnosis (Table 1).
Most of the higher costs observed among COPD
patients in the 2 years before and after diagnosis
are attributable to inpatient utilization (Fig. 3 and
Table 1). Of the 6864 COPD patients identiﬁed for this
study, 41.6% were hospitalized for COPD at least one
time during the study interval, and for 1222 patients
their ﬁrst COPD diagnosis was made during a hospi-
talization. The absolute and relative differences in
inpatient costs between COPD patients and their con-
trols do not change substantially after the diagnosis
of COPD is made; however, the primary reasons for
hospital admission do change (Table 2). Respiratory
symptom complaints including COPD, chronic bron-
chitis, and pneumonia become much more common in
the years after the COPD is diagnosed, accounting for
more than a third of the admissions.
Unexpectedly, renal failure was found to be the
leading cause for admission in the COPD case group in
the 2 years before initial diagnosis, and was much
higher among COPD patients than controls (Table 2).
To see whether costs related to renal failure were the
cause of most of the differences between the groups, we
ran an additional analysis after excluding all patients
with renal failure. Total cost differences between cases
and controls did decrease (24–13 months before index
month: $860; 12–1 months before index month:
$1703; at index month: $571; 1–12 months after index
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Figure 2 Mean total direct health-care costs
by month in the 24 months before and after the
month of initial chronic obstructive pulmonary
disease diagnosis.
Table 1 Summary of costs in the 2 years before and after the initial month of diagnosis ($)
Time period Visit type Case (95% CI) Control (95% CI)
Absolute
difference
Case is X greater
than control
24–13 months before index month IP 1,700 (1,184–2,216) 449 (358–539) 1,251 3.8
OP 3,670 (2,522–4,819) 3,720 (3,046–4,394) 50 1.0
RX 656 (612–700) 676 (651–701) 20 1.0
Total 6,026 (4,757–7,297) 4,844 (4,158–5,531) 1,182 1.2
12–1 months before index month IP 1,956 (1,420–2,492) 598 (484–711) 1,358 3.3
OP 5,900 (4,484–7,317) 5,100 (4,264–5,936) 800 1.2
RX 1,461 (1,399–1,522) 1,131 (1,102–1,159) 330 1.3
Total 9,317 (7,785–10,849) 6,828 (5,978–7,679) 2,489 1.4
Index month IP 226 (139–313) 73 (20–95) 153 3.1
OP 872 (463–1,281) 447 (339–555) 425 2.0
RX 276 (266–286) 108 (105–111) 168 2.6
Total 1,374 (953–1,795) 598 (487–708) 776 2.3
1–12 months after index month IP 1,621 (1,282–1,960) 719 (597–841) 902 2.3
OP 8,224 (6,030–10,419) 5,297 (4,444–6,150) 2,927 1.6
RX 2,191 (2,111–2,270) 1,099 (1,072–1,126) 1,092 2.0
Total 12,036 (9,800–14,271) 7,115 (6,248–7,981) 4,921 1.7
13–24 months after index month IP 1,907 (1,491–2,324) 632 (515–749) 1,275 3.0
OP 7,159 (4,859–9,458) 4,695 (3,916–5,475) 2,464 1.5
RX 1,293 (1,221–1,389) 655 (633–678) 638 2.0
Total 10,359 (7,994–12,725) 5,983 (5,189–6,777) 4,376 1.7
Costs are expressed as the mean in US dollars per person for the time period listed.
P-values for all differences were < 0.001 except for OP and RX in the 24–13 months before Index Month.
CI, conﬁdence interval; IP, inpatient; OP, outpatient; RX, outpatient pharmacy.
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month: $4311; 13–24 months after index month:
$4074), but remained highly signiﬁcant (P < 0.001 for
all differences).
Outpatient costs do not differ substantially between
case and control patients until just a few months
before the index month (Fig. 4 and Table 1). Neverthe-
less, a steady increase in outpatient costs is seen among
the COPD patients from thereafter, excepting a large
spiked increase in costs during the month of diagnosis.
A total of 4010 COPD patients (58.4%) were only
treated as outpatients during the study interval. In the
years after the initial COPD diagnosis, ofﬁce visits for
COPD and respiratory symptom complaints account
for 18% of overall outpatient utilization.
As with the outpatient health-care costs, there are
no substantial differences in pharmacy costs between
COPD cases and matched controls until just before the
initial diagnosis of COPD (Fig. 5 and Table 1). The
spiked increase in pharmacy costs at the time of diag-
nosis is more pronounced than that seen for either
inpatient or outpatient utilization. Outpatient phar-
macy costs for COPD patients are then appro-
ximately double those of the control group in the
2 years after the initial diagnosis, but only approxi-
mately 8% of prescription ﬁlls for COPD patients
during this period are attributable to respiratory drugs
(Table 3).
Discussion
Our study demonstrates that COPD patients have sub-
stantially higher direct medical costs in the 2 years
before their ﬁrst COPD diagnosis. Most of the
increased costs are attributable to hospitalizations.
Interestingly, the hospitalization rate does not change
after the initial diagnosis of COPD, but the reasons for
admission do change, with more than one-third of the
admissions after the diagnosis attributed to lung dis-
eases. The reasons for this change are not certain, but
this could represent either progression of the disease or
a heightened awareness among COPD patients and
their physicians about the contribution that lung
disease is making to their declining health. A remark-
ably high 17.8% of the cohort did not have a diagnosis
of COPD until they were hospitalized for it. Mean
pharmacy and outpatient visit costs did not increase
substantially until just 3 to 4 months before the index
date, but remained substantially higher thereafter. The
marginal cost increase among this limited cohort of
6864 COPD patients was more than $17 million in the
year before the initial diagnosis, and more than $25
million for the 2 years prior. This study conﬁrms that
undiagnosed COPD has a substantial impact on this
managed care system, and that there are several oppor-
tunities for improvement in both diagnosis and
treatment.
In our random chart review of 200 COPD patients,
we did ﬁnd evidence suggesting that the lung disease
component of the clinical presentation was often either
completely ignored or misdiagnosed. We found that
the average patient had very obvious risk factors,
such as an average 41-pack-year cigarette smoking
history, and 56.5% were documented to have at least
one chronic respiratory symptom. Implementation of
screening spirometry for all adults over the age of
45 years who have a smoking history and/or who have
chronic respiratory symptoms, as recommended by the
National Lung Health Education Project, could have
identiﬁed many of these COPD patients several years
earlier [11,12]. Spirometry also needs to be used more
consistently to conﬁrm the diagnosis. In terms of treat-
ment, the use of bronchodilators was very inconsistent,
and the use of respiratory medications after the initial
diagnosis declined rapidly. Earlier diagnosis of COPD
could lead to more timely interventions, including
smoking cessation and appropriate pharmacotherapy,
and may result in improved patient care and quality of
life [13].
There are several limitations to this study that must
be considered. The main limitation is the difﬁculty of
estimating the impact of a disease that has not been
diagnosed. Our main goal was to estimate the eco-
nomic impact of undiagnosed COPD, but for this
analysis we were limited to using only those persons
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Figure 3 Mean inpatient costs by month in the
24 months before and after the month of
initial chronic obstructive pulmonary disease
diagnosis.
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who have had a diagnosis of COPD at some point
during the study period. Undoubtedly, there are a large
number of persons with COPD in the LHP who simply
were never diagnosed, or who were only given the
diagnosis of COPD one time as an outpatient, and it is
impossible to know how much this misclassiﬁcation
error contributed to the observed differences between
the cases and controls. Another limitation is that
patients for our study were captured from one
managed care organization from one part of the
country. Although population-based studies such as
ours help to establish the validity of the ﬁndings, their
generalizability to other populations may be limited.
The differences between cases and controls may also be
Table 2 Primary hospital admission diagnoses by 12-month intervals before and after the index date in COPD cases and age- and
sex-matched controls
Case Control
ICD-9 (diagnosis) No. admits % of admits ICD-9 (diagnosis) No. admits % of admits
24–13 months before index month
1 585 Chronic renal failure 162 21.3 786.5 Chest pain NOS 262 16.7
2 786.5 Chest pain NOS 93 12.3 427.9 Arrhythmia NOS 203 13.0
3 427.9 Arrhythmia NOS 83 10.9 794.31 Abnormal ECG 105 6.7
4 794.31 Abnormal ECG 54 7.1 789 Abdominal pain NOS 68 4.3
5 486 Pneumonia 38 5.0 786.59 Chest pressure 67 4.3
6 428 Heart failure 33 4.3 427.31 Atrial ﬁbrillation 57 3.6
7 401.9 Hypertension 32 4.2 486 Pneumonia 57 3.6
8 714 Rheumatoid arthritis 26 3.4 780.79 Malaise or fatigue 55 3.5
9 427.31 Atrial ﬁbrillation 24 3.2 401.9 Hypertension 51 3.3
10 250 Diabetes mellitus 24 3.2 585 Chronic renal failure 51 3.3
12–1 months before index month
1 585 Chronic renal failure 263 15.2 786.5 Chest pain NOS 374 13.7
2 786.5 Chest pain NOS 227 13.1 427.9 Arrhythmia NOS 358 13.1
3 427.9 Arrhythmia NOS 214 12.4 789 Abdominal pain NOS 148 5.4
4 428 Heart failure 164 9.5 794.31 Abnormal ECG 143 5.2
5 486 Pneumonia 126 7.3 585 Chronic renal failure 124 4.5
6 794.31 Abnormal ECG 115 6.6 428 Heart failure 118 4.3
7 789 Abdominal pain NOS 77 4.4 427.31 Atrial ﬁbrillation 113 4.1
8 436 Cerebrovascular disease 69 4.0 436 Cerebrovascular disease 102 3.7
9 729.5 Pain in limb 68 3.9 414.01 Coronary artery disease 99 3.6
10 799 Ill-deﬁned causes 68 3.9 786.59 Chest pressure 98 3.6
Index month
1 496 COPD 392 10.1 427.9 Arrhythmia NOS 43 14.2
2 786.5 Chest pain NOS 348 9.0 786.5 Chest pain NOS 33 10.0
3 486 Pneumonia 286 7.4 427.31 Atrial ﬁbrillation 18 5.9
4 427.9 Arrhythmia NOS 283 7.3 428 Heart failure 16 5.3
5 428 Heart failure 192 4.9 794.31 Abnormal ECG 14 4.6
6 491.21 Chronic bronchitis 175 4.5 789 Abdominal pain NOS 13 4.3
7 786.09 Respiratory symptoms 167 4.3 585 Chronic renal failure 13 4.3
8 786.05 Respiratory symptoms 145 3.7 436 Cerebrovascular disease 13 4.3
9 794.31 Abnormal ECG 123 3.2 414.01 Coronary artery disease 12 4.0
10 799 Ill-deﬁned causes 118 3.0 250 Diabetes mellitus 11 3.6
1–12 months after index month
1 496 COPD 666 17.1 427.9 Arrhythmia NOS 529 14.3
2 786.5 Chest pain NOS 539 13.9 786.5 Chest pain NOS 489 13.2
3 427.9 Arrhythmia NOS 509 13.1 794.31 Abnormal ECG 259 7.0
4 428 Heart failure 436 11.2 436 Cerebrovascular disease 188 5.1
5 486 Pneumonia 418 10.9 427.31 Atrial ﬁbrillation 185 5.0
6 585 Chronic renal failure 393 10.1 428 Heart failure 184 5.0
7 786.09 Respiratory symptoms 260 6.7 789 Abdominal pain NOS 171 4.6
8 794.31 Abnormal ECG 226 5.8 585 Chronic renal failure 161 4.4
9 786.05 Respiratory symptoms 196 5.0 486 Pneumonia 147 4.0
10 491.21 Chronic bronchitis 189 4.9 780.79 Malaise or fatigue 140 3.8
13–24 months after index month
1 496 COPD 582 24.6 427.9 Arrhythmia NOS 474 12.6
2 427.9 Arrhythmia NOS 403 17.1 786.5 Chest pain NOS 444 11.6
3 786.5 Chest pain NOS 391 16.5 794.31 Abnormal ECG 213 5.6
4 428 Heart failure 259 11.0 436 Cerebrovascular disease 152 4.1
5 486 Pneumonia 241 10.2 789 Abdominal pain NOS 142 3.7
6 585 Chronic renal failure 225 9.5 585 Chronic renal failure 137 3.6
7 794.31 Abnormal ECG 212 9.0 427.31 Atrial ﬁbrillation 131 3.5
8 786.09 Respiratory symptoms 175 7.4 428 Heart failure 115 3.1
9 491.21 Chronic bronchitis 142 6.0 599 Urinary tract infection 115 3.1
10 786.05 Respiratory symptoms 114 4.8 486 Pneumonia 115 3.1
COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; NOS, not otherwise speciﬁed.
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confounded by the higher prevalence of comorbid
conditions such as heart disease among the COPD
patients. We used the Charlson Index to describe the
burden of prognostically signiﬁcant comorbidities in
our COPD and control populations, but the Charlson
Index only covers the major comorbidities as it was
originally developed to predict mortality. Other study
populations may have different prevalence of serious
comorbidities that will affect their overall utilization
rates. They also may have different mixes of disease
severity, which has been shown to have a signiﬁcant
impact on total direct costs in COPD [14].
To our knowledge, this is the ﬁrst study that exam-
ines the natural history of utilization among COPD
patients before and after the initial diagnosis of the
disease. Several recently published articles have exam-
ined COPD from a variety of perspectives. Some have
focused on national cost estimates, such as the study
by the National Heart, Lung, and Blood Institute
(NHLBI) which estimated that direct and indirect costs
totaled $37.2 billion in the United States in 2004, with
56% of this total attributable to direct costs [15]. Two
other studies using national data also estimated annual
direct costs to be in the range of $20 to $26 billion per
year, after adjustment for inﬂation [16,17]. The
NHLBI report found that 55% of direct costs were for
hospital and nursing home care, 24% were for pre-
scription drugs, and 18% were for outpatient physi-
cian services [15]. This suggests a much higher
proportion of cost for prescription drugs, and lower
cost for outpatient services, than what we have found
in our database, which we believe is due to limitations
in how prescription drug and outpatient utilization is
captured at the national level. Dividing the NHLBI’s
estimate of $20.8 billion in direct costs attributable to
COPD by the approximately 11 million diagnosed
COPD patients in the United States in 2004 yields an
average total cost of $1894 per patient, which is obvi-
ously far below our marginal COPD cost estimate of
$4921 in the ﬁrst year and $4376 in the second year
after initial diagnosis.
Our previous analysis of excess costs in COPD,
which captured patients in 1996 and then analyzed
their 1997 cost, found that COPD patients had total
direct costs that were approximately twice those of
controls, with the biggest proportional difference
found in costs for hospitalization [5]. An important
difference between this and our previous study is that
the controls selected in the ﬁrst study were not
required to have similar rates of utilization (i.e., at
least one hospitalization or two outpatient visits), so
the absolute differences between the cases and controls
were much greater. The total direct annual cost differ-
ence in 1997 was $5036, which would be the equiva-
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Figure 4 Mean outpatient costs by month in
the 24 months before and after the month of
initial chronic obstructive pulmonary disease
diagnosis.
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Figure 5 Mean pharmacy costs by month in
the 24 months before and after the month of
initial chronic obstructive pulmonary disease
diagnosis.
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lent of approximately $8000 today after adjustment
for health-care inﬂation. Approximately half of the
excess costs in our previous study were attributable to
comorbidities. Similar studies of Medicaid popula-
tions, which tend to be younger and have less comor-
bidities, have found annual direct costs in the $6000
range, with about a third of these attributable to
comorbidities [18]. The excess cost estimate derived
from the 2000 Medical Expenditure Panel Survey
(MEPS) data by Miller et al. also estimated marginal
cost differences in the $6000 range [19].
Attributable cost estimates for COPD are invariably
lower than marginal cost estimates, mostly because of
the fact that they do not capture the associated
smoking-related comorbidities. The methods used to
collect data in the attributable cost studies are also
highly variable; for example, some are population-
based studies of entire groups ofMedicaid patients [18],
while others rely on surveys of relatively small groups
[20]. In the study ofMedicaid patients, which used both
marginal and attributable cost approaches, Marton
et al. found attributable costs in the range of $2500 to
$2800 after adjustment for inﬂation [18]. In Miller
et al.’s study using the MEPS data, they estimated the
direct attributable cost of COPD to be a little more than
$3000 per patient, after adjustment for demographic
factors, smoking, and inﬂation [19]. In a survey of 462
patients who participated in the 1999 and 2000 US
Medicare Current Beneﬁciary Survey, Stuart et al. esti-
mated attributable costs of only slightly more than
$1000 after adjustment for inﬂation [20].
Conclusions
We have demonstrated that undiagnosed COPD has a
substantial impact on health-care utilization and costs,
especially for hospitalizations. As therapy changes
from the palliative approach of years past to aggressive
interventions aimed at reducing exacerbations and
improving survival and quality of life, it will become
more important to reduce the number of undiagnosed
cases and identify patients at earlier stages of the
disease [13].
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Table 3 Summary of pharmacy utilization in the 2 years before and after the initial month of diagnosis of COPD
Case Control
Drug category No. RX ﬁlls (%) Drug category No. RX ﬁlls (%)
24–13 months before index month
1 All other prescriptions 22,820 (42.2) All other prescriptions 75,687 (46.2)
2 Analgesics/psychotherapeutics 12,995 (24.0) Analgesics/psychotherapeutics 42,213 (25.8)
3 Cardiovascular 11,928 (22.1) Cardiovascular 29,787 (18.2)
4 Antibiotics 4,116 (7.6) Antibiotics 13,129 (8.0)
5 Respiratory 2,229 (4.1) Respiratory 2,967 (1.8)
12–1 months before index month
1 All other prescriptions 47,528 (41.9) All other prescriptions 118,213 (45.4)
2 Analgesics/Psychotherapeutics 26,584 (23.4) Analgesics/psychotherapeutics 68,153 (26.2)
3 Cardiovascular 23,238 (20.5) Cardiovascular 48,920 (18.8)
4 Antibiotics 9,034 (8.0) Antibiotics 20,670 (7.9)
5 Respiratory 7,128 (6.3) Respiratory 4,569 (1.8)
Index month
1 All other prescriptions 9,221 (40.0) All other prescriptions 11,595 (44.8)
2 Analgesics/psychotherapeutics 4,534 (19.7) Cardiovascular 6,928 (26.8)
3 Cardiovascular 4,013 (17.4) Analgesics/psychotherapeutics 4,843 (18.7)
4 Respiratory 2,680 (11.6) Antibiotics 2,070 (8.0)
5 Antibiotics 2,583 (11.2) Respiratory 425 (1.6)
1–12 months after index month
1 All other prescriptions 81,585 (42.3) All other prescriptions 129,354 (44.9)
2 Analgesics/psychotherapeutics 40,011 (20.8) Cardiovascular 78,196 (27.2)
3 Cardiovascular 39,340 (20.4) Analgesics/psychotherapeutics 54,196 (18.8)
4 Respiratory 16,892 (8.8) Antibiotics 21,725 (7.5)
5 Antibiotics 14,902 (7.7) Respiratory 4,464 (1.6)
13–24 months after index month
1 All other prescriptions 49,727 (42.8) All other prescriptions 80,584 (45.1)
2 Cardiovascular 24,097 (20.8) Cardiovascular 50,882 (28.4)
3 Analgesics/psychotherapeutics 23,572 (20.3) Analgesics/psychotherapeutics 32,488 (18.2)
4 Respiratory 9,758 (8.4) Antibiotics 12,592 (9.0)
5 Antibiotics 8,904 (7.7) Respiratory 2,320 (1.3)
COPD, chronic obstructive pulmonary disease; RX, outpatient pharmacy.
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SmithKline, and Schering-Plough Pharmaceuticals on COPD-
related topics. Drs Shah, Dastani, and Phillips are employed
by Boehringer Ingelheim. None of the rest of the coauthor-
shas a relationship with a company that could be viewed as a
potential conﬂict of interest.
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